Recludix Pharma Inc. has divulged signal transducer and activator of transcription 3 (STAT3) and 6 (STAT6) inhibitors reported to be useful for the treatment of cancer and inflammation.
Recludix Pharma Inc. has disclosed signal transducer and activator of transcription 3 (STAT3) and/or STAT6 inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
Huchembio Co. Ltd. has described signal transducer and activator of transcription 3 (STAT3) inhibitors reported to be useful for the treatment of autoimmune diseases, atherosclerosis, inflammatory disorders, cancer, diabetic retinopathy, diabetes, osteoporosis and viral infections.
Scientists from Sichuan University and affiliated organizations have discovered a new signal transducer and activator of transcription 3 (STAT3) inhibitor, being developed as a potential therapeutic candidate against idiopathic pulmonary fibrosis (IPF).
Oncolinx Pharmaceuticals LLC and the U.S. Department of Health and Human Services have presented new signal transducer and activator of transcription 3 (STAT3) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders, and bacterial and viral infections.
